News

Cereno Scientific‘s investigational oral therapy CS1 improves right heart function in people with pulmonary arterial hypertension (PAH), according to new data from a Phase 2a clinical trial. Three months of treatment also boosted quality of life, while symptoms associated with heart failure and the risk of clinical worsening…

Males with pulmonary arterial hypertension (PAH) have more proinflammatory macrophages — a type of immune cell — in the lungs than do females with the disease, a study suggests. Researchers identified 56 genes showing differing activity in macrophages taken from men and women with PAH, with this altered activity…

Lungpacer Medical’s AeroNova diaphragm neurostimulation system significantly reduced pulmonary hypertension (PH) among critically ill patients with lung failure while they were on mechanical ventilation, according to data from the STIMULUS trial. The device, which electrically stimulates nerves to activate the diaphragm muscles in synchrony with mechanical ventilation, also…

Implantation of the Aeson Total Artificial Heart — a device from Carmat designed to mimic the heart’s function — was able to help three advanced heart failure patients with pulmonary hypertension (PH) to become eligible for a heart transplant. The patients, who had previously been considered transplant-ineligible due…

Activation of an immune signaling molecule called STAT6 may lead to pulmonary hypertension (PH) in people with oxygen deprivation due to obstructive sleep apnea, according to a recent study in mice. Obstructive sleep apnea is a common sleep disorder characterized by chronic intermittent hypoxia, or repeated episodes of stopping…

An artificial intelligence (AI)-based algorithm is capable of detecting features of pulmonary hypertension (PH) by analyzing heart sounds recorded with a digital stethoscope, a study found. Eko Health developed the technology with the help of a $2.7 million National Institutes of Health (NIH) grant. The algorithm could…

Blocking GLS1, an enzyme that drives pro-inflammatory immune macrophages, reduces the signs and symptoms of pulmonary arterial hypertension (PAH) in rats, a study reports. “This study offers a fresh outlook upon understanding the role of macrophages in PAH and provides experimental evidence in developing targeted therapeutic strategies,” the researchers…

Anoikis, a form of programmed cell death, is involved in the development of chronic thromboembolic pulmonary hypertension (CTEPH), according to a genetic analysis study. Researchers identified two anoikis-related genes associated with CTEPH — PLAUR and HMOX1 — which may serve as diagnostic biomarkers or as…

Seralutinib, an inhaled therapy for pulmonary arterial hypertension (PAH) in the pipeline of Gossamer Bio, continues to reduce the resistance blood faces moving into the lungs when added to standard of care treatment for PAH, according to data from a long-term extension part of a Phase 2 clinical…

A single dose of the investigational therapy TX45 improved heart function and blood flow, or hemodynamics, in people with pulmonary hypertension and heart failure with preserved ejection fraction (PH-HFpEF), according to interim results from a Phase 1b clinical trial. The part of the study involving PH-HFpEF patients is completely…

Merck announced that its Phase 3 clinical trial HYPERION, which had been testing Winrevair (sotatercept-csrk) in people with recently diagnosed pulmonary arterial hypertension (PAH), will be ended early — a move that will allow all study participants, including those who had been assigned to receive a placebo,…

Men with pulmonary arterial hypertension (PAH) have a larger right heart size and worse survival rates than women, independent of body size and functional status, a study reports. Moreover, sex-specific mortality risk thresholds, with higher risk indicated by a larger area of the right pulmonary artery, as measured by…